Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Slides:

Advertisements

Similar presentations

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Advertisements

First-Line TKI Use in EGFR Mutation-Positive NSCLC

Volume 79, Issue 1, Pages (January 2013)

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV nonsmall-cell lung cancer (NSCLC) patients with good performance status.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Schematic representation of main EGFR-TKIs resistance mechanisms.

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Survival without tracheostomy

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. Successful tissue collection in patients.

Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.

A) Evolution of the proportion of virtual patients (VPs) that died or received a graft while on the high-priority list by year according to the scenario.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Detection rate for EGFR mutations in cfDNA.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

A) RON tyrosine kinase receptor structure; highlighted are the two somatic mutations detected in brain secondary lesions from lung cancers (R1136C and.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

A white elephant or the elephant in the room

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Clinical courses of patients.

Kaplan–Meier curves of long-term survival in young (

Detection rate of EGFR mutations in cfDNA by characteristics

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Phosphorylation levels of discoidin domain receptor (DDR)2.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor– Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR.

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

A–c) Case 1, with epidermal growth factor receptor (EGFR) exon 21 mutations (V843I and L858R). a) Pedigree chart. a–c) Case 1, with epidermal growth factor.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

Location of common clinically relevant mutations in EGFR

Kaplan–Meier curve for progression-free survival for non-Asian patients with epidermal growth factor receptor (EGFR) mutation-positive status in the INTEREST.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Receiver operating curves assessing the prognostic accuracy of a) N-terminal pro-brain natriuretic peptide, b) pro-atrial natriuretic peptide, c) high-sensitivity.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Presentation transcript:

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on different EGFR mutation types. Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on different EGFR mutation types. PFS curves of lung adenocarcinoma patients aged >50 and ≤50 years were plotted separately for patients with a) del-19, b) L858R and c) uncommon EGFR mutations. Shang-Gin Wu et al. ERJ Open Res 2017;3:00092-2016 ©2017 by European Respiratory Society